Evidence map›Paper›PMID 29119930›Full record

ReviewCurrent neuropharmacology2019

Anti-Oxidant Drugs: Novelties and Clinical Implications in Cerebellar Ataxias.

Emanuele Barca, Valentina Emmanuele, Salvatore DiMauro, Antonio Toscano, Catarina M Quinzii

Open access · bronzeAbstract readReview
In one paragraph

Review in Current neuropharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Emanuele BarcaDepartment of Neurology, Columbia University Medical Center, New York, NY, 10032, United States.
Valentina EmmanueleDepartment of Neurology, Columbia University Medical Center, New York, NY, 10032, United States.
Salvatore DiMauroDepartment of Neurology, Columbia University Medical Center, New York, NY, 10032, United States.
Antonio ToscanoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, 98125, Italy.
Catarina M QuinziiDepartment of Neurology, Columbia University Medical Center, New York, NY, 10032, United States.
Columbia University Irving Medical Center · USUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHereditary cerebellar ataxias are a group of disorders characterized by heterogeneous clinical manifestations, progressive clinical course, and diverse genetic causes. No disease modifying treatments are yet available for many of these disorders. Oxidative stress has been recurrently identified in different progressive cerebellar diseases, and it represents a widely investigated target for treatment.

objectiveTo review the main aspects and new perspectives of antioxidant therapy in cerebellar ataxias ranging from bench to bedside.

methodThis article is a summary of the state-of-the-art on the use of antioxidant molecules in cerebellar ataxia treatments. It also briefly summarizes aspects of oxidative stress production and general characteristics of antioxidant compounds.

resultsAntioxidants represent a vast category of compounds; old drugs have been extensively studied and modified in order to achieve better biological effects. Despite the vast body of literature present on the use of antioxidants in cerebellar ataxias, for the majority of these disorders conclusive results on the efficacy are still missing.

conclusionAntioxidant therapy in cerebellar ataxias is a promising field of investigations. To achieve the success in identifying the correct treatment more work needs to be done. In particular, a combined effort is needed by basic scientists in developing more efficient molecules, and by clinical researchers together with patients communities, to run clinical trials in order to identify conclusive treatments strategies.

Indexed as

AnimalsAntioxidantsCerebellar AtaxiaHumansOxidative StressAntioxidantsAntioxidantsataxiascerebellar ataxiacoenzyme Q10idebenoneoxidative stress.

Identifiers

PMID29119930
PMCPMC6341493
OpenAlexW2767423682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.